# Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis

> **NCT07235904** · PHASE4 · RECRUITING · sponsor: **University Hospital Schleswig-Holstein** · enrollment: 300 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Mirikizumab
- **DRUG:** Azathioprine (AZA)

## Key facts

- **NCT ID:** NCT07235904
- **Lead sponsor:** University Hospital Schleswig-Holstein
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2028-03
- **Final completion:** 2028-10
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07235904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07235904, "Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07235904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*